Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
David R. Gandara(University of California, Davis), Ryon P. Graf, Sarah Sammons(Dana-Farber Cancer Institute), Shilpa Gupta(Cleveland Clinic), Miles C. Andrews(Alfred Health), Richard S.P. Huang(TGS (United Kingdom)), Lilia Bouzit(Flatiron Health (United States)), Vivek Subbiah(Sarah Cannon), Gerald Li(Foundation Medicine (United States)), Geoffrey R. Oxnard(Foundation Medicine (United States)), Megan M. Price(Flatiron Health (United States)), David P. Carbone(Vanderbilt University), Júlia C.F. Quintanilha, Ramez N. Eskander(University of California San Diego), Samuel J. Klempner(Broad Institute), Jonathan W. Riess(University of California Davis Medical Center), Jeremy Snider(University of Washington), Cheryl Cho-Phan(Flatiron Health (United States)), Jeffrey S. Ross(Unknown), Amit Mahipal(Dana-Farber Cancer Institute), Neeraj Agarwal(University of Utah), David Fabrizio(Foundation Medicine (United States))
Cited by 48
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k